about
Imaging of Myocardial Fibrosis in Patients with End-Stage Renal Disease: Current Limitations and Future PossibilitiesHemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function.Tissue-advanced glycation end product concentration in dialysis patients.Endotoxaemia in haemodialysis: a novel factor in erythropoetin resistance?Sometimes when you hear hoof beats, it could be a zebra: consider the diagnosis of Fabry diseaseCirculating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney diseaseElevated levels of procoagulant plasma microvesicles in dialysis patients.Patient and Staff Perceptions of Intradialytic Exercise before and after Implementation: A Qualitative Study.Hyperphosphatemia, Phosphoprotein Phosphatases, and Microparticle Release in Vascular Endothelial Cells.Design and methods of CYCLE-HD: improving cardiovascular health in patients with end stage renal disease using a structured programme of exercise: a randomised control trial.Troponin T for the detection of dialysis-induced myocardial stunning in hemodialysis patients.A 4-month programme of in-centre nocturnal haemodialysis was associated with improvements in patient outcomes.Inflammatory factors and exercise in chronic kidney disease.Pediatric myocardial stunning underscores the cardiac toxicity of conventional hemodialysis treatmentsHemodialysis-induced cardiac injury: determinants and associated outcomes.Investigating the effects of 6 months extended duration, in-centre nocturnal versus conventional haemodialysis treatment: a non-randomised, controlled feasibility studyInduction treatment of previously undiagnosed ANCA-associated vasculitis in a renal transplant patient with Rituximab.Native T1 mapping: inter-study, inter-observer and inter-center reproducibility in hemodialysis patients.Exercise in kidney disease and diabetes: time for action.Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow.Epicardial adipose tissue in patients with end-stage renal disease on haemodialysis.The importance of accurate measurement of aortic stiffness in patients with chronic kidney disease and end-stage renal disease.Intestinal Barrier Disturbances in Haemodialysis Patients: Mechanisms, Consequences, and Therapeutic Options.The Potential Cardiovascular Benefits of Low-Glucose Degradation Product, Biocompatible Peritoneal Dialysis Fluids: A Review of the Literature.Differences in medical care usage between two mass-gathering sporting events.Novel cardiac nuclear magnetic resonance method for noninvasive assessment of myocardial fibrosis in hemodialysis patients.The use of T1 mapping to define myocardial fibrosis in haemodialysis patients.Motivations and barriers to exercise in chronic kidney disease: a qualitative study.A delayed case of radiation nephropathy.Categorization of the hemodynamic response to hemodialysis: the importance of baroreflex sensitivity.'There is nothing more deceptive than an obvious fact': more evidence for the prescription of exercise during haemodialysis (intradialytic exercise) is still required.Regular exercise during haemodialysis promotes an anti-inflammatory leucocyte profile.Symptom burden in patients with chronic kidney disease not requiring renal replacement therapy.Cardiac Remodelling in Patients Undergoing in-Centre Nocturnal Haemodialysis: Results from the MIDNIGHT Study, a Non-Randomized Controlled Trial.Potentially pathogenic circulating autoantibodies to cardiac troponin are present in hemodialysis patients.The Impact of Exercising During Haemodialysis on Blood Pressure, Markers of Cardiac Injury and Systemic Inflammation--Preliminary Results of a Pilot Study.Effects of intradialytic cycling exercise on exercise capacity, quality of life, physical function and cardiovascular measures in adult haemodialysis patients: a systematic review and meta-analysis.Microparticles and Exercise in Clinical PopulationsExercise during hemodialysis does not affect the phenotype or prothrombotic nature of microparticles but alters their proinflammatory functionRenal association commentary on the KDIGO (2017) clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD
P50
Q30360334-F8FB49DD-9948-467A-B552-42B2F3A65C46Q33560543-6C581A3F-ED52-4259-BEEB-111CBBA62C24Q33571288-64D0B62D-AC5A-46E1-A72B-A7D1F3EAFB77Q34328779-C80E43A3-D886-4166-B2ED-7A8123708F24Q34360126-0E54F2BA-E17A-47D2-9B00-24824E0B7B34Q34497186-BC6B3965-E7E4-4975-96A2-D88A7154A52BQ34927281-56489F7D-6CD8-4B19-A16B-6C14A1A3D49DQ35662024-F16CCC1F-8D31-4EF0-AE91-7CD35410122FQ36003122-F33E7042-B31B-420B-8F6B-708D11038B2AQ36071494-C770FC6E-F2FD-4870-B7DE-C86A9E46F825Q36126885-A63C418C-4D79-42FA-8966-2E95AD017279Q36306779-BBF55BE5-6FF0-42D1-8295-DD567383CE03Q36882794-0E71227F-2C78-472E-9EF8-E499C3C2DD2AQ37152510-D9B5779E-34A9-478C-AB51-D39C6D5C884DQ37176822-971BEF34-797E-4B7E-A2E9-551A343EF62FQ37251682-E4069E96-D5DE-465D-BAF1-25543533A201Q37302171-66EAB29C-E1DF-41E3-A340-D2D910834A6EQ37668262-53FD4303-0439-43D0-A665-48E282A093ACQ37986134-17FA113C-1DC5-4BE4-811F-8A311669C046Q38571160-B21198CB-5DF8-4245-806C-B2F9BCBF4253Q38579817-303E1CD1-C6C1-4723-BA3C-EBEBA9C931E7Q38635835-B36E8003-481B-4BD0-B836-71A7E3C8130AQ38757951-96F0737A-4EEE-4196-8E0D-9CFB3DB21192Q39414143-01FAA7CA-49EF-40DA-8A88-41702B3E824DQ39572522-7586E6A5-CD53-469A-8893-617B41D31778Q40538468-13487A2B-5CD4-4BE5-BAE3-B306C3BE7A23Q40715504-27DBB890-CCCE-4BDE-836E-646EE771093AQ40856226-FF03DCD8-FF20-43D7-9CDF-923B9349847BQ41682298-EF6EAAAB-A042-4494-9F84-2258FD449D85Q43248683-424B8BAC-587C-4EC2-A0C5-DE8D8B2B3553Q44018289-0263AD71-44D0-42CD-9F56-0CBEA3F1187EQ47097463-F673712C-60DA-4E4A-8BDD-385FC77145E8Q47101781-5C5E670F-CE24-4063-A849-628411DDEA33Q50223912-697A6ACC-3964-47AF-8B4B-E18A5B51CCEBQ51315246-C2D08851-DC8A-4EAD-AEE3-53B9058D6A82Q53260147-B0137C04-0421-40D3-977B-585291C991EDQ53278043-A67E5624-3E33-4A31-8D22-56668D150627Q57133476-A5D5AAC9-DD7B-49EF-B9ED-3D3FA5A2D19CQ57192749-B85AEA73-7C8F-4968-9002-31AD63C559A7Q57823250-8462D398-75B2-4671-B05B-78E3BDF21AD1
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
James O Burton
@nl
James O Burton
@sl
James O. Burton
@en
James O. Burton
@es
type
label
James O Burton
@nl
James O Burton
@sl
James O. Burton
@en
James O. Burton
@es
prefLabel
James O Burton
@nl
James O Burton
@sl
James O. Burton
@en
James O. Burton
@es
P106
P1153
16027855400
P2002
drjamesburton
P2038
James_Burton2
P21
P31
P496
0000-0003-1176-7592